Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food-Effect Study of LEO 32731 in Healthy Subjects
NCT02126371Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of orismilast in Psoriasis vulgaris (PV), sponsored by LEO Pharma. Primary endpoint: Area under the plasma concentration versus time curve at 1 week. Started May 2014; status: completed.
02
Drugs
orismilast
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02126371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126371.